Przejdź do zawartości
Merck
  • 1-Deoxy-D-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell lines.

1-Deoxy-D-galactonojirimycins with dansyl capped N-substituents as β-galactosidase inhibitors and potential probes for GM1 gangliosidosis affected cell lines.

Carbohydrate research (2011-06-08)
Richard F G Fröhlich, Richard H Furneaux, Don J Mahuran, Robert Saf, Arnold E Stütz, Michael B Tropak, Jacqueline Wicki, Stephen G Withers, Tanja M Wrodnigg
ABSTRAKT

Two simple and reliably accessible intermediates, N-carboxypentyl- and N-aminohexyl-1-deoxy-D-galactonojirimycin were employed for the synthesis of a set of terminally N-dansyl substituted derivatives. Reaction of the terminal carboxylic acid of N-carboxypentyl-1-deoxy-D-galactonojirimycin with N-dansyl-1,6-diaminohexane provided the chain-extended fluorescent derivative. Employing bis(6-dansylaminohexyl)amine, the corresponding branched di-N-dansyl compound was obtained. Partially protected N-aminohexyl-1-deoxy-D-galactonojirimycin served as intermediate for two additional chain-extended fluorescent 1-deoxy-D-galactonojirimycin (1-DGJ) derivatives featuring terminal dansyl groups in the N-alkyl substituent. These new compounds are strong inhibitors of d-galactosidases and may serve as leads en route to pharmacological chaperones for GM1-gangliosidosis.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
Hexamethylenediamine, technical grade, 70%
Sigma-Aldrich
Hexamethylenediamine, 98%
Sigma-Aldrich
Hexamethylenediamine dihydrochloride, 99%